Expert Opinion on the Prescription Practice of Rabeprazole and Other Common Proton Pump Inhibitors for Patients with Gastroesophageal Reflux Disease
Asian Journal of Medicine and Health · pp. 1–7 · Published 15 Feb 2024
10.9734/ajmah/2024/v22i3986Abstract
Objective: The current survey-based study aims to provide further insights on expert opinion regarding the commonly prescribed PPIs in clinical practice, with a specific focus on the use of oral rabeprazole 20 mg as a treatment for gastroesophageal reflux disease (GERD) maintenance therapy in Indian settings. Methodology: The questionnaire-based survey involving 25 questions collected perspectives of experts across various regions of India regarding the prescription practice of rabeprazole 20 mg and other proton-pump inhibitors (PPIs) for treating GERD symptoms. Results: Out of 512 study participants, 44% reported obesity as the common comorbid condition observed in GERD patients, while 28% noted co-morbid diabetes mellitus. According to 68% of the respondents, rabeprazole demonstrated superiority over other PPIs in terms of quicker onset of action, maintaining intragastric pH >4 over 24 hours’ post-dose, and reduced nighttime heartburn. For GERD patients with functional dyspepsia and gastroparesis, 52% of responders favored the addition of domperidone as a prokinetic drug to the PPI treatment. Moreover, the majority of participants (61.91%) observed that rabeprazole 20 mg did not cause a delay in stomach emptying, nor did it raise somatostatin levels or alter baseline motilin levels in GERD patients. These findings underscore the effectiveness of rabeprazole 20 mg in comparison to omeprazole and lansoprazole. Conclusion: Experts recommended rabeprazole 20 mg as the preferred treatment option over omeprazole and lansoprazole for GERD patients with coexisting obesity and diabetes mellitus conditions. Additionally, over half of the respondents reported using a combination of domperidone and other PPIs for GERD patients with functional dyspepsia and gastroparesis.
References (10)
- 1 Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma [DOI]
- 2 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease [DOI]
- 3 Esomeprazole 40�mg provides more effective intragastric acid control than lansoprazole 30�mg, omeprazole 20�mg, pantoprazole 40�mg and rabeprazole 20�mg in patients with gastro-oesophageal reflux symptoms [DOI]
- 4 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease [DOI]
- 5 Comorbidities are Frequent in Patients with Gastroesophageal Reflux Disease in a Tertiary Health Care Hospital [DOI]
- 6 Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
- 7 Clinical trial: the treatment of gastro‐oesophageal reflux disease in primary care – prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg [DOI]
- 8 An Expert Review and Recommendations on the Rational Use of Proton Pump Inhibitors: Indian Perspective.
- 9 Comparison of morning and evening administration of rabeprazole for gastro‐oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double‐blind, cross‐over study [DOI]
- 10 Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety [DOI]
Cited by 2
Hemant Juneja, S. Gambhir, K. H. Junaidy · Journal of Association of Physicians of India · 2025
Showing 1 of 2 known citations — external sources report more than can currently be individually listed.
Related research
- Cardiac vs. Non Cardiac Chest Pain: Prospect of Different Pathological and Physiological Etiologies and Managements — shares topic coverage
- Esophageal Dysmotility in Patients with Gastroesophageal Reflux Disease — shares topic coverage
- Expert Opinion on the Prescription Practice of Proton Pump Inhibitors in Indian Settings for Managing Gastro-Esophageal Reflux Diseases — shares topic coverage
- Expert Opinion on the Prescription Practice of Proton Pump Inhibitor for the Treatment of Gastroesophageal Reflux Disease — shares topic coverage
- Validated Spectrophotometric Method for Determination of Some Benzimidazole Derivatives in Pharmaceutical Formulations Using 1,2-naphthoquinone-4-sulphonate — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
2
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.